Ellis P E, Fong L F Wong Te, Rolfe K J, Crow J C, Reid W M N, Davidson T, MacLean A B, Perrett C W
Department of Obstetrics and Gynaecology, Royal Free & University College Medical School (Royal Free Campus), London, United Kingdom.
Gynecol Oncol. 2002 Aug;86(2):150-6. doi: 10.1006/gyno.2002.6629.
Paget's disease of the vulva (PDV) and Paget's disease of the breast (PDB) are uncommon diseases, accounting for approximately 1% of all vulval neoplasms and 0.5-4% of all breast cancers, respectively. In 10-30% of vulval cases an invasive adenocarcinoma is present. In such cases the disease is often aggressive and recurrence rate is high. This is in contrast to PDB where the general consensus is that almost all cases are associated with an in situ or invasive ductal carcinoma. Our aim was to examine the presence of the tumor suppressor protein p53 and the proliferation marker Ki67 in PDV and PDB and correlate any differences in the expression of these two proteins with the presence of an underlying carcinoma.
Immunohistochemistry was performed on 52 archival cases of PDV, which included 10 with associated invasive adenocarcinoma of the vulva, and on 37 archival cases of PDB, including 26 with available associated ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast. All cases were formalin-fixed and paraffin wax-embedded. Monoclonal antibodies were used with microwave antigen retrieval. Streptavidin-biotin-horseradish peroxidase and 3,3'-diaminobenzidine detection methods were employed to visualize antibody binding and staining. A section was scored positive for p53 if more than 10% of cell nuclei were stained brown and Ki67 was expressed as a percentage of positive cells to the nearest 5% of cells showing nuclear positivity (Ki67 staining index).
p53 was expressed in 15 of 52 (29%) PDV cases and 5 of 37 (13%) cases of PDB. Four of the ten cases (40%) of PDV associated with invasive disease expressed p53 compared with 11 of 42 (26%) cases without invasive disease. The mean Ki67 staining index for PDV associated with invasion was 19%, and for that without invasion, 16%. In the breast cases, the mean staining index was 11%.
Our data suggest that p53 may have a role to play in PDV progression, and may be a late event in some cases, especially those associated with invasive disease. Ki67 has no apparent prognostic role in PDV as there was no significant difference between those cases associated with and those without invasive disease. Neither p53 nor Ki67 appears to have a prognostic role to play in PDB.
外阴佩吉特病(PDV)和乳腺佩吉特病(PDB)均为罕见疾病,分别约占所有外阴肿瘤的1%和所有乳腺癌的0.5 - 4%。在10% - 30%的外阴病例中存在浸润性腺癌。在此类病例中,疾病往往具有侵袭性且复发率高。这与PDB形成对比,普遍共识是几乎所有PDB病例都与原位或浸润性导管癌相关。我们的目的是检测肿瘤抑制蛋白p53和增殖标志物Ki67在PDV和PDB中的表达情况,并将这两种蛋白表达的差异与潜在癌的存在相关联。
对52例存档的PDV病例进行免疫组化检测,其中包括10例伴有外阴浸润性腺癌的病例;对37例存档的PDB病例进行检测,其中包括26例伴有乳腺原位导管癌(DCIS)或浸润癌的病例。所有病例均经福尔马林固定、石蜡包埋。使用单克隆抗体并采用微波抗原修复。采用链霉亲和素 - 生物素 - 辣根过氧化物酶和3,3'-二氨基联苯胺检测方法来观察抗体结合及染色情况。若超过10%的细胞核被染成棕色,则该切片p53染色为阳性;Ki67以阳性细胞占显示核阳性细胞的百分比表示(Ki67染色指数),精确到最接近的5%。
52例PDV病例中有15例(29%)表达p53,37例PDB病例中有5例(13%)表达p53。10例伴有浸润性疾病的PDV病例中有4例(40%)表达p53,而42例无浸润性疾病的病例中有11例(26%)表达p53。与浸润相关的PDV病例的平均Ki67染色指数为19%,无浸润的病例为16%。在乳腺病例中,平均染色指数为11%。
我们的数据表明p53可能在PDV进展中起作用,并且在某些情况下可能是一个晚期事件,特别是那些与浸润性疾病相关的病例。Ki67在PDV中没有明显的预后作用,因为伴有浸润性疾病和无浸润性疾病的病例之间没有显著差异。p53和Ki67在PDB中似乎均无预后作用。